A recent study published in Cannabis and Cannabinoid Research, further examined the health implications that may come from cannabis use specific to kidney disease. Researchers affiliated with Johns Hopkins University School of Medicine (Baltimore, Maryland) and Tulane University (New Orleans, Louisiana), utilized longitudinal data stemming from Baltimore, Maryland regarding the connection between kidney function and cannabis use.

A recently published review examined the research on the use of cannabinoids for atopic dermatitis (AD). As the study explains, this skin disease can result in itching, dry skin, and inflammation from the loss of function of the skin barrier. Adverse effects associated with long term use of topical treatments containing glucocorticoids point to the need for alternatives, the researchers explain, also noting that some studies have examined cannabinol (CBD) and tetrahydrocannabinol (THC) alongside palmitoyletanolamide (PEA) and dronabinol for anti-inflammatory and anti-itch properties. The study, “Therapeutic potential of cannabinoids for treating atopic dermatitis,” was published in the Journal of Cannabis Research in August 2025, and focused on cannabis compounds including natural and synthetic, clinical and preclinical evidence, and legislative challenges.

Can cannabis help cancer patients live longer, speed wound healing, or ease Alzheimer’s symptoms? Dr. Dustin Sulak explores new research surrounding these questions in the September 2025 webinar. Dr. Sulak, an osteopathic general practitioner, founder of Healer, a cannabis education and product resource, presented the latest installment of this monthly webinar series intended to discuss recent research on medical cannabis for various conditions.

Hemp-derived CBD oil may help lessen symptoms of anxiety, a recently published pilot study demonstrated. Affecting more than a third of adults in the US, anxiety is of the most common symptoms reported to be treated by cannabis, the study notes. The researchers in this investigation tested a full-spectrum, high-CBD hemp extract the similar to formulations and doses available commercially on symptoms of anxiety. The pilot study, “Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study,” was published in Biomedicines in August 2025.

A recent study published in the Journal of Oral Pathology & Medicine, investigated whether there was an increased risk of head and neck cancers through cannabis use.

Data showed that cannabis use is not “independently associated with an elevated risk of head and neck cancers.” Researchers with the study were connected with the University of Florida at Gainesville (Gainesville, Florida). No association was discovered once researchers considered alcohol and tobacco use with participants. When looking at these variables, investigators became aware that there was a link with them and an increased risk of cancer.